Randomized controlled trial of postoperative radiotherapy and shortterm time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer

被引:150
作者
Tveit, KM
Guldvog, I
Hagen, S
Trondsen, E
Harbitz, T
Nygaard, K
Nilsen, JB
Wist, E
Hannisdal, E
机构
[1] NORWEGIAN RADIUM HOSP, OSLO, NORWAY
[2] AKERSHUS CENT HOSP, NORDBYHAGEN, NORTH IRELAND
[3] AKER HOSP, OSLO, NORWAY
[4] TELEMARK CENT HOSP, SKIEN, NORWAY
[5] TROMSO REG HOSP, TROMSO, NORWAY
关键词
D O I
10.1046/j.1365-2168.1997.02863.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background The purpose of the present study was to investigate whether a 1-month regimen of postoperative radiotherapy combined with 5-fluorouracil could reduce the local recurrence rate and improve survival in patients with Dukes B and C rectal cancer. Methods One hundred and forty-four patients were randomized to surgery alone or surgery combined with postoperative radiotherapy (46 Gy) and bolus 5-fluorouracil 30 min before six of the radiotherapy fractions. One hundred and thirty-six patients were eligible. Results The adjuvant treatment was well tolerated. After an observation time of 4-8 years, patients in the adjuvant treatment group had a cumulative local recurrence rate of 12 per cent compared with 30 per cent in the group that had surgery only (P = 0.01). The 5-year recurrence-free and overall survival rate was 64 per cent in the adjuvant group compared with 46 per cent (P = 0.01) and 50 per cent (P = 0.05) respectively in the surgery group. The adjusted relative risk of recurrence and death for the adjuvant group was 0.48 (95 per cent confidence interval 0.28-0.82) and 0.56 (0.33-0.94) respectively. Conclusion The 1-month postoperative combination regimen improved treatment results in patients with Dukes B and C rectal cancer, id terms of local recurrence rate, recurrence-free survival and overall survival, without serious side-effects.
引用
收藏
页码:1130 / 1135
页数:6
相关论文
共 28 条
[1]  
[Anonymous], 1990, Cancer, V66, P49
[2]  
[Anonymous], 1992, J Clin Oncol, V10, P549
[3]  
BALSLEV IB, 1986, CANCER-AM CANCER SOC, V58, P22, DOI 10.1002/1097-0142(19860701)58:1<22::AID-CNCR2820580106>3.0.CO
[4]  
2-Q
[5]  
BUYSE M, 1988, JAMA-J AM MED ASSOC, V259, P3571
[6]   PHARMACOLOGIC REQUIREMENTS FOR OBTAINING SENSITIZATION OF HUMAN-TUMOR CELLS-INVITRO TO COMBINED 5-FLUOROURACIL OR FTORAFUR AND X-RAYS [J].
BYFIELD, JE ;
CALABROJONES, P ;
KLISAK, I ;
KULHANIAN, F .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1982, 8 (11) :1923-1933
[7]  
COX DR, 1972, J R STAT SOC B, V34, P187
[8]  
DAHL O, 1990, CANCER-AM CANCER SOC, V66, P2286, DOI 10.1002/1097-0142(19901201)66:11<2286::AID-CNCR2820661106>3.0.CO
[9]  
2-T
[10]  
Dixon WJ, 1990, BMDP STAT SOFTWARE